In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
Visiting attendees represented some of the top names in in the industry.
Sam McNeal, Ph.D., and Michael Sweeney have joined the Technology Ventures staff.
Networking, lab tours highlight first OMRF BioVenture Forum
Technology Ventures works to pair scientists with industry partners.
As Vice President of Technology Ventures, Manu Nair is focused on building partnerships with industry that advance the research in OMRF’s laboratories and translate our discoveries into diagnostics and therapeutics for human disease. Nair holds a Masters in Business Administration from Lamar University and a Masters of Law from the Franklin Pierce Law Center of […]